ARBUTUS BIOPHARMA CORP (ABUS) Institutional Ownership Changes & 13F Activity
ARBUTUS BIOPHARMA CORP (ABUS). Institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC Form 13F filings (Q2 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions in the latest reporting period. Notable filers include Goldman Sachs Group Inc, Adar1 Capital Management, Llc, Nomura Holdings Inc, State Street Corp, and Bank Of America Corp.
| Institution | Type | Change in shares | Change Position % | Shares | Reported stock balance | Portfolio quarter | Filing date |
|---|---|---|---|---|---|---|---|
| State Street Corp | Buy | +1,526,669 | +24.1% | 7,869,179 | $37.77M | Q2 2026 | Sep 22, 2026 |
| Manufacturers Life Insurance Company, The | Buy | +1,876 | +4.4% | 44,305 | $212.66K | Q2 2026 | Sep 09, 2026 |
| Citadel Advisors Llc | Sell | -272,442 | -40.2% | 404,696 | $1.94M | Q2 2026 | Sep 02, 2026 |
| California State Teachers Retirement System | Buy | +42,675 | +29.8% | 185,660 | $891.17K | Q2 2026 | Aug 24, 2026 |
| Mercer Global Advisors Inc | Sell | -1,260 | -6.5% | 18,085 | $86.81K | Q2 2026 | Aug 19, 2026 |
| Jefferies Financial Group Inc. | Sell | -182,395 | -9.6% | 1,711,672 | $8.22M | Q2 2026 | Aug 17, 2026 |
| Goldman Sachs Group Inc | Buy | +2,406,368 | +218.7% | 3,506,802 | $16.83M | Q2 2026 | Aug 14, 2026 |
| Adar1 Capital Management, Llc | Sell | -1,865,028 | -59.5% | 1,268,147 | $6.09M | Q2 2026 | Aug 14, 2026 |
| Nomura Holdings Inc | Buy | +1,637,081 | — | 1,637,081 | $7.86M | Q2 2026 | Aug 14, 2026 |
| Bank Of America Corp | Buy | +962,569 | +57.2% | 2,646,197 | $12.70M | Q2 2026 | Aug 14, 2026 |
| Rubric Capital Management Lp | Buy | +906,548 | +13.7% | 7,532,937 | $36.16M | Q2 2026 | Aug 14, 2026 |
| Whitefort Capital Management, Lp | Buy | +863,376 | +5.8% | 15,794,261 | $75.81M | Q2 2026 | Aug 14, 2026 |
| Man Group Plc | Buy | +473,467 | — | 473,467 | $2.27M | Q2 2026 | Aug 14, 2026 |
| Deltroit Asset Management (Uk) Llp | Buy | +400,000 | +50.0% | 1,200,000 | $5.76M | Q2 2026 | Aug 14, 2026 |
| Woodline Partners Lp | Buy | +271,684 | +13.5% | 2,281,856 | $10.95M | Q2 2026 | Aug 14, 2026 |
| Quinn Opportunity Partners Llc | Sell | -259,299 | -50.4% | 255,214 | $1.23M | Q2 2026 | Aug 14, 2026 |
| Invesco Ltd. | Buy | +250,907 | — | 250,907 | $1.20M | Q2 2026 | Aug 14, 2026 |
| Susquehanna Portfolio Strategies, Llc | Buy | +244,865 | +1301.1% | 263,685 | $1.27M | Q2 2026 | Aug 14, 2026 |
| D. E. Shaw & Co., Inc. | Buy | +238,662 | +166.7% | 381,863 | $1.83M | Q2 2026 | Aug 14, 2026 |
| Squarepoint Ops Llc | Buy | +208,145 | — | 208,145 | $999.10K | Q2 2026 | Aug 14, 2026 |
| Hudson Bay Capital Management Lp | Sell | -200,000 | -57.1% | 150,000 | $720.00K | Q2 2026 | Aug 14, 2026 |
| State Of Wisconsin Investment Board | Buy | +153,658 | +173.9% | 242,017 | $1.16M | Q2 2026 | Aug 14, 2026 |
| Barclays Plc | Sell | -108,181 | -2.5% | 4,207,914 | $20.20M | Q2 2026 | Aug 14, 2026 |
| Wells Fargo & Company/Mn | Buy | +89,285 | +152.1% | 147,994 | $710.37K | Q2 2026 | Aug 14, 2026 |
| Two Sigma Investments, Lp | Buy | +84,986 | — | 84,986 | $407.93K | Q2 2026 | Aug 14, 2026 |
| Integrated Quantitative Investments Llc | Buy | +79,937 | — | 79,937 | $383.70K | Q2 2026 | Aug 14, 2026 |
| Legal & General Group Plc | Buy | +64,738 | +2.7% | 2,466,127 | $11.84M | Q2 2026 | Aug 14, 2026 |
| Xtx Topco Ltd | Buy | +36,189 | +90.4% | 76,210 | $365.81K | Q2 2026 | Aug 14, 2026 |
| Charles Schwab Investment Management Inc | Buy | +30,061 | +2.1% | 1,431,218 | $6.87M | Q2 2026 | Aug 14, 2026 |
| Exome Asset Management Llc | Sell | -25,318 | -33.5% | 50,166 | $240.80K | Q2 2026 | Aug 14, 2026 |
Frequently asked questions about ABUS activity
Which institutional owners are buying ABUS?
Institutional owners buying ABUS include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in ABUS activity?
"Buy" means an investor increased their reported position in ABUS compared to the prior reporting period. This reflects growing exposure to ARBUTUS BIOPHARMA CORP (ABUS) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in ABUS increasing?
Institutional interest in ABUS can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.
Related ABUS Institutional Insights
- ABUS Overview
- ABUS 13F Institutional Holders
- ABUS Superinvestors
- Healthcare Sector Institutional Ownership
- Healthcare Sector Portfolio Overlap
- Institutional Portfolio Overlap & Shared Holdings
- Most Bought Healthcare Stocks By Institutional Investors
- Most Sold Healthcare Stocks By Institutional Investors
- ABUS Insider Trading & SEC Form 4 Activity
- ABUS Articles
- Top Institutional Investor Stock Rankings